已上市化学药品药学变更研究技术指导原则(试行)

2021-02-10 国家药品监督管理局药品审评中心(CDE) NMPA

已上市化学药品药学变更研究技术指导原则(试行)

中文标题:

已上市化学药品药学变更研究技术指导原则(试行)

发布日期:

2021-02-10

简要介绍:

已上市化学药品药学变更研究技术指导原则(试行)

相关资料下载:
[AttachmentFileName(sort=1, fileName=已上市化学药品药学变更研究技术指导原则(试行).pdf)] GetToolGuiderByIdResponse(projectId=1, id=aa4b61c0020622a3, title=已上市化学药品药学变更研究技术指导原则(试行), enTitle=, guiderFrom=NMPA, authorId=0, author=, summary=已上市化学药品药学变更研究技术指导原则(试行), cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心(CDE), associationIntro=国家药品监督管理局药品审评中心(CDE), copyright=0, guiderPublishedTime=Wed Feb 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>已上市化学药品药学变更研究技术指导原则(试行)</p>, tagList=[TagDto(tagId=32646, tagName=化学药品)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4999, appHits=24, showAppHits=0, pcHits=2268, showPcHits=4975, likes=0, shares=10, comments=3, approvalStatus=1, publishedTime=Fri Feb 19 22:54:06 CST 2021, publishedTimeString=2021-02-10, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Feb 19 22:53:58 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 11:48:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=已上市化学药品药学变更研究技术指导原则(试行).pdf)])
已上市化学药品药学变更研究技术指导原则(试行).pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=925908, encodeId=aaf59259080c, content=明白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=092f5461579, createdName=ms1000000987981057, createdTime=Sat Feb 20 20:08:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925887, encodeId=d99892588ece, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Feb 20 17:57:41 CST 2021, time=2021-02-20, status=1, ipAttribution=)]
    2021-02-20 ms1000000987981057

    明白

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=925908, encodeId=aaf59259080c, content=明白, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=092f5461579, createdName=ms1000000987981057, createdTime=Sat Feb 20 20:08:01 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925887, encodeId=d99892588ece, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Feb 20 17:57:41 CST 2021, time=2021-02-20, status=1, ipAttribution=)]
    2021-02-20 zb1235672

    学习了

    0